AMAM Stock - Ambrx Biopharma Inc.
Unlock GoAI Insights for AMAM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|
| Revenue | $7.40M | $7.46M | $13.67M | $10.31M |
| Gross Profit | $7.40M | $7.46M | $13.67M | $10.31M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-57,081,000 | $-64,424,000 | $-13,115,000 | $-22,472,000 |
| Net Income | $-77,996,000 | $-68,288,000 | $-17,839,000 | $-22,313,000 |
| Net Margin | -1053.7% | -916.0% | -130.5% | -216.4% |
| EPS | $-2.02 | $-3.34 | $-0.47 | $-0.59 |
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 25th 2023 | JMP Securities | Initiation | Mkt Outperform | $15 |
| September 12th 2023 | BTIG Research | Initiation | Buy | $26 |
| July 31st 2023 | RBC Capital Mkts | Initiation | Outperform | $29 |
| June 14th 2023 | B. Riley Securities | Initiation | Buy | $26 |
| June 2nd 2023 | Oppenheimer | Initiation | Outperform | $30 |
| May 19th 2023 | Cantor Fitzgerald | Initiation | Overweight | $25 |
| April 7th 2022 | Robert W. Baird | Initiation | Outperform | $16 |
Earnings History & Surprises
AMAMEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2023 | Nov 16, 2023 | $-0.19 | $-0.37 | -94.7% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-0.09 | $-0.35 | -288.9% | ✗ MISS |
Q2 2023 | May 11, 2023 | — | $-0.05 | — | — |
Q2 2023 | Apr 25, 2023 | — | $-0.34 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.34 | — | — |
Q3 2022 | Aug 29, 2022 | $-0.08 | $-1.33 | -1562.5% | ✗ MISS |
Q2 2022 | Apr 26, 2022 | $-0.08 | $-1.04 | -1195.3% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | — | $-0.59 | — | — |
Q4 2021 | Oct 28, 2021 | $-0.07 | $-5.72 | -8072.4% | ✗ MISS |
Q3 2021 | Sep 30, 2021 | — | $-0.51 | — | — |
Q2 2021 | Jun 21, 2021 | — | $-0.41 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-5.72 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.41 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.14 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-0.14 | — | — |
Latest News
Frequently Asked Questions about AMAM
What is AMAM's current stock price?
What is the analyst price target for AMAM?
What sector is Ambrx Biopharma Inc. in?
What is AMAM's market cap?
Does AMAM pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to AMAM for comparison